Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Conformis (CFMS) stocks in Canada

Learn how to easily invest in Conformis stocks.

Conformis is a medical devices business based in the US. Conformis stocks (CFMS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.17 – an increase of 16.47% over the previous week. Conformis employs 259 staff and has a trailing 12-month revenue of around $101.1 million.

How to buy shares in Conformis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CFMS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Conformis stock price (NASDAQ:CFMS)

Use our graph to track the performance of CFMS stocks over time.

Conformis shares at a glance

Information last updated 2022-01-17.
Latest market close$0.78
52-week range$0.65 - $1.96
50-day moving average $0.86
200-day moving average $1.11
Wall St. target price$2.00
PE ratio 14.8422
Dividend yield N/A (0%)
Earnings per share (TTM) $0.05

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Conformis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Conformis price performance over time

Historical closes compared with the close of $0.778 from 2022-01-21

1 week (2022-01-12) 12.88%
1 month (2021-12-18) N/A
3 months (2021-10-22) -38.74%
6 months (2021-07-22) -42.79%
1 year (2021-01-22) -44.43%
2 years (2020-01-22) -31.75%
3 years (2019-01-22) 50.75%
5 years (2017-01-20) 8.6

Is Conformis under- or over-valued?

Valuing Conformis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Conformis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Conformis's P/E ratio

Conformis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Conformis shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Conformis's PEG ratio

Conformis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.21. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Conformis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Conformis's EBITDA

Conformis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.2 million.

The EBITDA is a measure of a Conformis's overall financial performance and is widely used to measure a its profitability.

Conformis financials

Revenue TTM $101.1 million
Operating margin TTM 2.98%
Gross profit TTM $33.7 million
Return on assets TTM 1.58%
Return on equity TTM 10.4%
Profit margin 6.86%
Book value $0.62
Market capitalisation $124.3 million

TTM: trailing 12 months

Conformis share dividends

We're not expecting Conformis to pay a dividend over the next 12 months.

Conformis share price volatility

Over the last 12 months, Conformis's shares have ranged in value from as little as $0.65 up to $1.955. A popular way to gauge a stock's volatility is its "beta".

CFMS.US volatility(beta: 1.3)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Conformis's is 1.3031. This would suggest that Conformis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Conformis overview

Conformis, Inc. , a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site